vebicorvir + entecavir + pegylated interferon alpha

This is a **combination therapy** consisting of three active drugs: - **Vebicorvir** is a core protein allosteric modulator (CpAM) developed for the treatment of chronic hepatitis B virus (HBV) infection. It works by inhibiting the formation of functional HBV capsids, thereby disrupting HBV replication. - **Entecavir** is a guanosine nucleoside analogue with potent antiviral activity against HBV, acting as a reverse transcriptase inhibitor and blocking HBV DNA polymerase activity. - **Pegylated interferon alpha** is a long-acting form of interferon with antiviral and immunomodulatory properties. It enhances the host immune response against HBV by activating immune cells and increasing cytokine production. The combination is under research for the **treatment of chronic hepatitis B (CHB)**, aiming to achieve a **functional cure** (HBsAg clearance and HBV DNA suppression). Combination regimens with entecavir and pegylated interferon alpha have demonstrated improved rates of HBsAg seroconversion and viral suppression over monotherapy[1][3][4]. Development of the full triple combination (vebicorvir + entecavir + pegylated interferon alpha) is at the investigational stage, with ongoing or recent clinical trials.